Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04538742 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
A Phase 1 study of Metastatic Breast Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 245
- Enrollment target
- 20
- Study locations
NCT04538742: Active Phase 1 study of Metastatic Breast Cancer, sponsored by AstraZeneca.
NCT04538742 is a Phase 1 study of Metastatic Breast Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 245 participants, above the 203-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (21% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04538742, a Phase 1 study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 245 participants
- Enrollment target
- 20
- Study locations
Study Summary
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer
Primary Outcome
Occurrence of AEs in Part 1 graded according to NCI CTCAE v5.0
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Trastuzumab deruxtecan
- DRUG Tucatinib
- DRUG Durvalumab
- DRUG Pertuzumab
Study Locations (20)
Other
- Research Site - Melbourne
- Research Site - Barretos
- Research Site - Belo Horizonte
- Research Site - Natal
- Research Site - Porto Alegre
- Research Site - Porto Alegre
- Research Site - Rio de Janeiro
- Research Site - São Paulo
- Research Site - São Paulo
- Research Site - Sorocaba
New York
- Research Site - Commack
- Research Site - Harrison
- Research Site - New York
- Research Site - New York
Florida
- Research Site - Fort Myers
- Research Site - St. Petersburg
Ohio
- Research Site - Columbus
Tennessee
- Research Site - Nashville
Texas
- Research Site - Fort Worth
Virginia
- Research Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2020-12-28 |
| Est. Completion | 2030-01-31 |
| Phase | Phase 1 |
What the registry record for NCT04538742 still lists
NCT04538742 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, above the 203-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (21% higher).
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Paclitaxel is the first listed.
NCT04538742 names 20 study sites across 7 states, led by Other, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT04538742 about?
NCT04538742 is a clinical study titled "A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer". DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer
What is the current status of trial NCT04538742?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 245 participants. The study started on 2020-12-28. Estimated completion is 2030-01-31.
What conditions does trial NCT04538742 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT04538742?
The interventions under investigation include: Paclitaxel (DRUG), Trastuzumab deruxtecan (DRUG), Tucatinib (DRUG), Durvalumab (DRUG), Pertuzumab (DRUG).
Who is sponsoring clinical trial NCT04538742?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04538742 being conducted?
This trial has 20 study locations across Florida, New York, Ohio, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04538742's enrollment target sits among peer trials
245 24th of 139 higher than 116 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI